Onkologie. 2023:17(1):31-34 | DOI: 10.36290/xon.2023.008

The use of PET/MRI in rectal cancer

Andrea Šprláková-Puková1, Hana Petrášová1, Alexandra Litavcová1, Zdeněk Kala2, Lenka Ostřížková3, Marek Dostál1, 4
1 Klinika radiologie a nukleární medicíny, LF MU a FN Brno
2 Chirurgická klinika, LF MU a FN Brno
3 Interní hematoonkologická klinika, LF MU a FN Brno
4 Biofyzikální ústav, LF MU Brno

Magnetic resonance is currently a key examination for rectal tumors invading through muscularis propria. The reason is accurate TNM staging and selection of appropriate treatment. The use of PET/MRI combines the possibility not only to examine the rectum and performe T staging, but it can help delineate extent of tumor better and also better characterize small lymph nodes and improve detection of distant metastases. The use of hepatospeific contrast agent improves detection and specification of the focal liver lesion. This aproach called one - stop - shop ensures to determine TNM classification in one examination. Moreover, this approach is beneficial from the patient´s point of view and it also saves examination times on other modalities and ultimately reduces the overall costs of diagnosis.

Keywords: rectal cancer, PET, MR, TNM classification.

Accepted: February 22, 2023; Published: March 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šprláková-Puková A, Petrášová H, Litavcová A, Kala Z, Ostřížková L, Dostál M. The use of PET/MRI in rectal cancer. Onkologie. 2023;17(1):31-34. doi: 10.36290/xon.2023.008.
Download citation

References

  1. Epidemiologie zhoubných nádorů v České republice. [Internet] [cited 2022 Dec 12]. Available from: www.svod.cz.
  2. Kim SH, Song BI, Kim BW, et al. Predictive Value of [18F]FDG PET/CT for Lymph Node Metastasis in Rectal Cancer. Sci Rep. 2019;9:4979. Available from: https://doi.org/10.1038/s41598-019-41422-8. Go to original source... Go to PubMed...
  3. Hope TA, Kassam Z, Loening A, et al. Paspulati R. The use of PET/MRI for imaging rectal cancer. Abdom Radiol (NY). 2019;Nov;44(11):3559-3568. doi: 10.1007/s00261-019-02089-x. PMID: 31201431; PMCID: PMC7001508. Go to original source... Go to PubMed...
  4. Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, et al. MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management. Radiographics. 2019;39(2):367-387. doi: 10.1148/rg.2019180114. Epub 2019 Feb 15. PMID: 30768361; PMCID: PMC6438362. Go to original source... Go to PubMed...
  5. Buchbender C, Heusner TA, Lauenstein TC, et al. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53(6):928-938. doi: 10.2967/jnumed.112.105338. Epub 2012 May 11. PMID: 22582048. Go to original source... Go to PubMed...
  6. Rosenkrantz AB, Friedman K, Chandarana H, et al. Current Status of Hybrid PET/MRI in Oncologic Imaging. AJR Am J Roentgenol. 2016;206(1):162-172. doi: 10.2214/AJR.15.14968. Epub 2015 Oct 22. PMID: 26491894; PMCID: PMC4915069. Go to original source... Go to PubMed...
  7. Cerny M, Dunet V, Rebecchini C, et al. Response of locally advanced rectal cancer (LARC) to radiochemotherapy: DW-MRI and multiparametric PET/CT in correlation with histopathology. Nuklearmedizin. 2019;58(1):28-38. English. doi: 10.1055/a-0809-4670. Epub 2019 Feb 15. PMID: 30769371. Go to original source... Go to PubMed...
  8. Langman G, Patel A, Bowley DM. Size and distribution of lymph nodes in rectal cancer resection specimens. Dis Colon Rectum. 2015;58(4):406-414. doi: 10.1097/DCR. 0000000000000321. PMID: 25751797. Go to original source... Go to PubMed...
  9. Lahaye MJ, Beets GL, Engelen SM, et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes? Radiology. 2009;252(1):81-91. doi: 10.1148/radiol.2521081364. Epub 2009 Apr 29. PMID: 19403848. Go to original source... Go to PubMed...
  10. Cho EY, Kim SH, Yoon JH, et al. Apparent diffusion coefficient for discriminating metastatic from non-metastatic lymph nodes in primary rectal cancer. Eur J Radiol. 2013;82(11):e662-668. doi: 10.1016/j.ejrad.2013.08.007. Epub 2013 Aug 12. PMID: 24016824. Go to original source... Go to PubMed...
  11. Cerny M, Dunet V, Prior JO, et al. Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT. Clin Nucl Med. 2016;41(4):289-295. doi: 10.1097/RLU.0000000000001172. PMID: 26828149; PMCID: PMC4851242. Go to original source... Go to PubMed...
  12. Heijnen LA, Lambregts DM, Mondal D, et al. Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol. 2013;23(12):3354-3360. doi: 10.1007/s00330-013-2952-5. Epub 2013 Jul 3. PMID: 23821022. Go to original source... Go to PubMed...
  13. Park MJ, Kim SH, Lee SJ, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology. 2011;260(3):771-780. doi: 10.1148/radiol.11102135. PMID: 21846762. Go to original source... Go to PubMed...
  14. Hope TA, Pampaloni MH, Nakakura E, et al. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015;40(6):1432-1440. doi: 10.1007/s00261-015-0409-9. PMID: 25820755. Go to original source... Go to PubMed...
  15. Kang B, Lee JM, Song YS, et al. Added Value of Integrated Whole-Body PET/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT. AJR Am J Roentgenol. 2016;206(1):W10-20. doi: 10.2214/AJR.14.13818. PMID: 26700358. Go to original source... Go to PubMed...
  16. Litavcová A, Dostál M, Keřkovský M, et al. Klinicko ekonomický potenciál PET/MR při staging karcinomu rekta. Ces Radiol. 2021;75(1):45-51. Go to original source...
  17. Furtado FS, Suarez-Weiss KE, Vangel M, et al. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer. 2021;125(7):975-982. doi: 10.1038/s41416-021-01494-8. Epub 2021 Jul 19. PMID: 34282295; PMCID: PMC8476553. Go to original source... Go to PubMed...
  18. Jeong JH, Cho IH, Chun KA, et al. Correlation Between Apparent Diffusion Coefficients and Standardized Uptake Values in Hybrid (18)F-FDG PET/MR: Preliminary Results in Rectal Cancer. Nucl Med Mol Imaging. 2016;50(2):150-156. doi: 10.1007/s13139-015-0390-9. Epub 2016 Jan 13. PMID: 27275364; PMCID: PMC4870464. Go to original source... Go to PubMed...
  19. Chandarana H, Heacock L, Rakheja R, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology. 2013;268(3):874-881. doi: 10.1148/radiol.13130620. Epub 2013 Jun 4. PMID: 23737537. Go to original source... Go to PubMed...
  20. Burris NS, Johnson KM, Larson PE, et al. Detection of Small Pulmonary Nodules with Ultrashort Echo Time Sequences in Oncology Patients by Using a PET/MR System. Radiology. 2016;278(1):239-246. doi: 10.1148/radiol.2015150489. Epub 2015 Jul 2. PMID: 26133050; PMCID: PMC4699498. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.